Polymer 3D printing and additive manufacturing solutions provider Stratasys Ltd. (NASDAQ: SSYS) announced on Monday that it is collaborating with healthcare technology company Siemens Healthineers in a pioneering research project to advance medical imaging phantoms for computed tomography (CT) imaging.
CT phantoms, crucial in medical imaging, simulate human body characteristics to evaluate CT scanner performance. The joint project uses Stratasys' PolyJet technology and RadioMatrix technology, along with Siemens Healthineers' advanced algorithm, aiming to create tailored phantoms with ultra-realistic human anatomy characteristics.
This collaboration may revolutionise medical phantom utilisation, potentially replacing human cadavers with 3D printed structures, providing efficiencies and minimising human variability.
The research will produce valuable data for advancing CT system algorithms, materials development and unlocking new application areas. The phased project starts with 3D printed phantoms for head and neck anatomies, leading to a Phase One endpoint of 3D printing a heart model and an entire human torso with complete radiographic accuracy.
Teva's Prolia biosimilar candidate accepted for review by FDA and EMA
Boehringer receives Breakthrough Therapy designation for survodutide
IRLAB Therapeutics reports start of Phase I study for IRL757
GBI Biomanufacturing agrees manufacturing collaboration with Allterum Therapeutics
MediLink enters clinical trial collaboration and supply agreement with Amgen
Innovent Biologics partners with Jiangsu Aosaikang Pharmaceutical for lung cancer treatment
Selonterra receives second grant from Michael J Fox Foundation for Parkinson's Research
Genprex research collaborators to present positive data on Reqorsa Gene Therapy at SITC 2024
Thermo Fisher Scientific announces expanded biopharma services
GE HealthCare reports promising Phase I results for innovative manganese-based MRI contrast agent
hVIVO reports positive results from RSV antiviral human challenge trial
TiumBio doses first patient in phase two TU2218 clinical trial
BerGenBio reveals preliminary safety data from Phase 1b BGBC016 study in first-line NSCLC patients
ABL Bio signs clinical trial collaboration and supply agreement with MSD